OpenAI Executive Brad Lightcap to Leave for New AI Venture 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
ADNOC Gas Targets Up to $4B Profit in 2026 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
US Judge Dismisses Gautam Adani Criminal Charges 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Add as a preferred source on Google
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
